Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic Patients (GATE2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04648423 |
|
Recruitment Status :
Completed
First Posted : December 1, 2020
Last Update Posted : December 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alcohol Use Disorder (AUD) Alcohol Dependence | Drug: Sodium Oxybate Drug: Placebo | Phase 4 |
Alcohol dependence (AD) is the most severe form of alcohol use disorder. It occurs in 2.6% of people aged 15+ years worldwide and can result in a reduction of life-expectancy by several years as compared with the general population.
Currently, disulfiram, acamprosate and naltrexone are the main medicinal products registered for the maintenance of abstinence in AD patients. Although effective on the group level, effects sizes are limited, and many AD patients fail to respond to these medications. Therefore, additional pharmacological treatments are needed.
Sodium oxybate 50mg/kg/day showed evidence of efficacy compared to placebo and naltrexone in the maintenance of abstinence in AD patients in a series of open label and blinded randomized controlled trials (RCTs). However, studies were generally small and did not investigate the sustainability of the Sodium oxybate effect post-treatment.
The present phase III/IV RCT (GATE 2) aimed to confirm the efficacy and safety of oral Sodium oxybate in the maintenance of abstinence. Secondary aims included the assessment of sustained SMO effects during the 6-month medication free period immediately following the 6-month treatment period and monitoring the risk of Sodium oxybate dependence.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 314 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | double-blind, placebo-controlled study with parallel group |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | The control medication (placebo) was identically-looking and identically tasting as active. |
| Primary Purpose: | Treatment |
| Official Title: | Multinational, Multicentre, Double-blind, Placebo-controlled Evaluation of the Efficacy of GHB in the Long-term Maintenance of Abstinence in Alcoholic Patients After the Initial Weaning Phase, Stratified by Lesch's Taxonomy (GATE 2) |
| Actual Study Start Date : | July 23, 2001 |
| Actual Primary Completion Date : | March 2011 |
| Actual Study Completion Date : | January 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: sodium oxybate
Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
|
Drug: Sodium Oxybate
solution for oral administration
Other Name: gamma-hydroxy butyrate (GHB) |
|
Placebo Comparator: placebo
Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
|
Drug: Placebo
solution for oral administration |
- Cumulative Abstinence Duration (CAD) [ Time Frame: 6-month treatment period ]to demonstrate that sodium oxybate is superior to placebo in the CAD during the treatment period.
- CAD stratified [ Time Frame: 6-month treatment period ]CAD during treatment period according to subtype patients stratified by Lesch's categories.
- Assessment of the exposure-corrected CAD [ Time Frame: 6-month treatment period ]assessment of the exposure-corrected cumulative abstinence duration (CCAD) during treatment.
- CAD during the whole study [ Time Frame: 12 months: 6-month treatment period + 6-month follow-up ]CAD during the whole observation period
- Proportion of abstinent patients [ Time Frame: 12 months: 6-month treatment period + 6-month follow-up ]proportion of abstinent patients at the end of the 6-month treatment period and at the end of the entire observation period.
- Time to the first relapse [ Time Frame: 6-month treatment period ]assessment of the time to the first relapse during the treatment period.
- Change from baseline in the craving for alcohol intensity and frequency by the Lubecker Craving Risiko Ruckfall (LCRR) questionnaire. [ Time Frame: 12 months: 6-month treatment period + 6-month follow-up ]
The LCRR provides the patient's current state about his craving for alcohol. The clinician interviews the patient to rate the intensity of the desire for alcohol (item-1) on a 4-point scale ranging from 1 (no desire) to 4 (very strong desire), and to rate the frequency of the desire for alcohol (item-2) on a 6-point scale ranging from 1 (never) to 6 (nearly continuous).
Higher scores mean a worse outcome.
- Assessment of the time course of γ-GT as biological marker of alcohol abuse, during treatment and at the end of follow-up. [ Time Frame: Month 6 ]γ-GT values
- Adverse events [ Time Frame: 6-month treatment period ]evaluation of the frequency, nature and severity of adverse clinical events, including mortality and morbidity
- Number of participants with Adverse Events (AEs) [ Time Frame: 6-month treatment period ]Overview of AEs.
- Risk of Secondary Dependence - treatment period [ Time Frame: 6-month treatment period ]
Evaluation of the risk of onset of dependence from the medication, by means of a 2-item questionnaire. The first to rate the intensity of the desire for medication since the last visit in a scale ranging from 0 to 100. The second to rate the approach to the next dose in a scale ranging from 1 (I just waited for the time to come) to 6 (I took the dose sooner than planned).
Higher scores mean a worse outcome.
- Assessment of the time course of MCV as biological marker of alcohol abuse, during treatment and at the end of follow-up. [ Time Frame: Month 6 ]MCV values
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The following subjects were recruited:
- males and females;
- of any ethnic group;
- age between 21 and 75 years at recruitment;
- documented alcohol dependency before weaning detected according to the CAGE instrument, classified according to the DSM-IV and ICD-10 and severity rated according to the MALT instrument;
- classified according to Lesch typology;
- having successfully undergone a detoxification program, encompassing a 10-day treatment period and a subsequent 10-day untreated follow-up;
- with a responsible relative or caregiver;
- having issued the informed consent.
Exclusion Criteria:
- subjects who did not quit alcohol drinking after the detoxification period;
- subjects with history of epilepsy or epileptics seizures not properly controlled by established anti-epileptic treatment;
- subjects with dependence from narcotics or other drugs of abuse;
- subjects without a stable address;
- subjects without a reference relative or caregiver;
- subjects with renai failure (blood creatinine >2.5 mg/dL and/or documented proteinuria >500 mg/day);
- subjects with heart failure or severe respiratory failure;
- subjects with hepatic encephalopathy stage lI-IV;
- subjects with severe psychiatric disorders requiring treatment with psychoactive medications (excluding short-term benzodiazepine treatments);
- subjects under treatment with clonidine, disulfiram (after the end of the detoxification period), haloperidol, bromocryptine, serotonine re-uptake inhibitors or other serotoninergic agents;
- female subjects who cannot assure not to become pregnant during the 7-month period covering treatment and the first treatment-free month of follow-up;
- documented pre-existent hypersensitivity to GHB;
- subjects unable or unwilling to issue the informed consent;
- participating to another clinica! investigation in the previous month prior to recruitment; 15. any other medicai condition which, according to the investigator, justifies the patient's exclusion from the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04648423
| Study Chair: | Roberto Cacciaglia | Laboratorio Farmaceutico C.T. |
| Responsible Party: | Laboratorio Farmaceutico Ct S.r.l. |
| ClinicalTrials.gov Identifier: | NCT04648423 |
| Other Study ID Numbers: |
GHBCR00/2 |
| First Posted: | December 1, 2020 Key Record Dates |
| Last Update Posted: | December 4, 2020 |
| Last Verified: | November 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
alcoholism alcohol alcohol dependence relapse prevention |
|
Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Sodium Oxybate |
Adjuvants, Anesthesia Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |